RxDoctor Payments Data

Shervin Shafa, MD

Gastroenterology · Washington, DCNPI 1922254051

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,950 of the $13,301 with a category attached, or 67.3%. Pentax Of America, Inc. accounts for 70.6% of it on its own, with 9 other manufacturers making up the rest.

$13,301in general payments, 2019–2025

Across 46 payments — averaging $289.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pentax Of America, Inc.$9K
  • Endogastric Solutions, Inc$2K
  • Boston Scientific$1K
  • Merit Medical Systems Inc$241
  • Sanofi$130
  • Pfizer$92
  • plus $133 from 4 others
$12,100in research payments, 2019–2025

Across 1 payment — averaging $12,100 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$12K

What the payments were for

  • Consulting fees$8,95067%
  • Travel & lodging$2,38318%
  • Food & beverage$1,96815%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,301 in reported general payments places this provider in the 85th percentile of 77 gastroenterology providers in District of Columbia.

See all gastroenterology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$115,083
Medicare patients
374
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pantoprazole Sodium58$936
Omeprazole32$539
Sucralfate12$536

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →